Zafgen (ZFGN) reports Q4 loss per share of 39c, to suspend plans to file IND application for ZGN-1258

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. NVDA
6. MSFT
7. SPY
8. SKYD
9. BBIO
10. RCKT

Go back to Zafgen (ZFGN) reports Q4 loss per share of 39c, to suspend plans to file IND application for ZGN-1258

Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates

March 11, 2019 4:05 PM EDT

Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061

Updates on progress preparing for FDA Type A meeting for ZGN-1061

Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies

Expanded executive team with highly experienced drug development leader, Dr. Priya Singhal, as Head of Research and Development

Company to host conference call today at 5:00 p.m. ET

BOSTON, March 11, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:... More